Abstract: Provided are stable formulations of anti-CD73 antibodies, which include 5-50 mM histidine, 2%-20% (w/v) trehalose, and 0.015%-0.05% (w/v) polysorbate 80 (PS80), at pH 5.6-6.4. Also provided are lyophilized compositions that can be obtained by drying the aqueous formulations and methods for treating diseases.

Abstract: A parvovirus vectors with a viral genome having a covalently closed end (ccePV vectors), methods for producing such vectors and DNA constructs used for producing such vectors.

Abstract: A recombination parvovirus vector that comprises a parvovirus capsid and a double-stranded vector genome having a sense-strand and an antisense-strand. The sense-strand comprises in the 5? to 3? direction: a parvovirus terminal repeat at the 5? end a coding sequence of a gene of interest (GOI); and a parvovirus terminal repeat at the 3? end. The vector genome further comprises a RNA destabilization/destruction domain (RDDD).

Abstract: A method for preparing an infectious, recombinant virus vector comprises the steps of: (a) infecting host cells with a first virus comprising an encapsidation defective adenovirus (edAd), the edAd comprising a first defective virus genome; (b) incubating the infected host cells in a culture medium for a period of time sufficient for producing infectious virus particles; and (c) recovering infectious virus particles secreted into a culture supernatant, wherein the edAd or the host cells comprise a second defective virus genome engineered to express a target gene of interest, wherein the edAd or the host cells comprise nucleic acid sequences sufficient for expressing adenovirus (Ad) helper genes necessary for replication of the defective virus DNA; and wherein the edAd or the host cells comprise nucleic acid sequences sufficient from expressing helper functions necessary for producing infectious, replication defective virus particles corresponding to the second virus.